Paul Calabresi Award for Clinical Oncology (K12)

The summary for the Paul Calabresi Award for Clinical Oncology (K12) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Paul Calabresi Award for Clinical Oncology (K12): This PA announces the replacement of the NCI Institutional Clinical Oncology Research Career Development (K12) Program (PAR-03-083 at http://grants.nih.gov/grants/guide/pa-files/PAR-03-083.html) with the Paul Calabresi Award for Clinical Oncology (K12) or PCACO. The purpose of the PCACO is to increase the number of medical doctors (M.D.'s, D.O.'s), and doctorally-degreed nurses (Ph.D.s or equivalents) and basic scientists (Ph.D.s D.V.M.s, or equivalents) who are highly-motivated and trained to: 1) perform clinical oncology therapeutic research that develops and tests scientific hypotheses based on fundamental and clinical research findings; 2) design and test hypothesis-based, clinical therapeutic protocols and adjunct biological analyses and for clinician candidates to administer all phases (i.e., pilot/Phase I, Phase II, and Phase III) of cancer therapeutic clinical trials, and (3) conduct cancer therapeutic research in team research settings in which basic and clinical scientists collaborate and interact to expedite the translation of basic research discoveries into patient-oriented therapeutic cancer research. The PCACO is not intended to train laboratory-based scientists whose research will emphasize the use of animal or other model systems. For the purposes of this award, and in agreement with the recommendations of the NIH Directors Panel on Clinical Research, (http://www.nih.gov/news/crp/97report/index.htm), patient-oriented research is defined as research conducted with human subjects (or on material of human origin such as tissues, specimens and cognitive phenomena) for which an investigator directly interacts with human subjects. This area of research includes 1) mechanisms of human disease; 2) therapeutic interventions; 3) clinical trials, and; 4) the development of new technologies. Studies falling under Exemption 4 for human subjects research are not included in this definition. The NCI has named this award in honor of the late Dr. Paul Calabresi, who was a pioneer in the pharmacological treatment of cancer and early translational research. It recognizes him for his humanity, dedication to his patients, mentorship of young clinical oncologists, contributions to understanding and curing of cancer, untiring efforts to promote and develop the field of clinical oncology, and ceaseless service to the National Cancer Institute including his participation in the strategic development of the Nations War on Cancer. Most of all, this award is intended to symbolize the quality and excellence of the physician scientists and the non-clinician translational researchers that NCI hopes will become critical contributors to the future elimination of death and suffering from cancer. Individuals with medical degrees seeking a career development experience exclusively in laboratory-based research should refer to the NIH Mentored Clinical Scientist Career Development Award or K08 at the following website: http://grants.nih.gov/grants/guide/pa-files/PA-00-003.html. Individuals with medical degrees interested in patient- oriented research should refer to the NIH Mentored Patient-Oriented Research Career Development Award or K23 at the following website: http://grants.nih.gov/grants/guide/pa-files/PA-00-004.html. Postdoctoral individuals (e.g., Ph.D.s) trained in laboratory-based research, who wish to change direction and focus their research careers on human cancer, should refer to the NCI Howard Temin Award or K01 at the following website: http://grants.nih.gov/grants/guide/pa-files/PAR-03-104.html.